Product Description
Eplerenone is used alone or in combination with other medications to treat high blood pressure. Eplerenone is in a class of medications called mineralocorticoid receptor antagonists. It works by blocking the action of aldosterone, a natural substance in the body that raises blood pressure. (Sourced from: https://medlineplus.gov/druginfo/meds/a603004.html)
Mechanisms of Action: Mineralocorticoid Receptor Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, France, United Kingdom
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Heart Failure|Hypertension|Kidney Diseases|Kidney Transplant|Myocardial Infarction|Renal Transplant
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2024-517408-12-00 | P3 |
Unknown Status |
Kidney Transplant|Renal Transplant|Kidney Diseases |
2031-08-03 |
|
| StratMedMINOCA | P2 |
Recruiting |
Myocardial Infarction |
2026-07-31 |
|
| CPRC2018/EVATRAN | P3 |
Unknown Status |
Kidney Transplant |
2026-03-12 |
|
| CTR20131433 | P3 |
Active, not recruiting |
Myocardial Infarction|Hypertension|Heart Failure |
None |